BriaCell Therapeutics Statistics
Total Valuation
BCTX has a market cap or net worth of $23.92 million. The enterprise value is $1.12 million.
| Market Cap | 23.92M |
| Enterprise Value | 1.12M |
Important Dates
The last earnings date was Tuesday, June 9, 2026, after market close.
| Earnings Date | Jun 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BCTX has 8.70 million shares outstanding. The number of shares has increased by 1,260.31% in one year.
| Current Share Class | 8.70M |
| Shares Outstanding | 8.70M |
| Shares Change (YoY) | +1,260.31% |
| Shares Change (QoQ) | +158.73% |
| Owned by Insiders (%) | 2.10% |
| Owned by Institutions (%) | 6.33% |
| Float | 7.86M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.02 |
| P/TBV Ratio | 1.00 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.07
| Current Ratio | 7.07 |
| Quick Ratio | 7.07 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -866.15 |
Financial Efficiency
Return on equity (ROE) is -175.25% and return on invested capital (ROIC) is -113.26%.
| Return on Equity (ROE) | -175.25% |
| Return on Assets (ROA) | -90.84% |
| Return on Invested Capital (ROIC) | -113.26% |
| Return on Capital Employed (ROCE) | -136.41% |
| Weighted Average Cost of Capital (WACC) | 13.29% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.92M |
| Employee Count | 16 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -92.06% in the last 52 weeks. The beta is 1.64, so BCTX's price volatility has been higher than the market average.
| Beta (5Y) | 1.64 |
| 52-Week Price Change | -92.06% |
| 50-Day Moving Average | 3.83 |
| 200-Day Moving Average | 6.83 |
| Relative Strength Index (RSI) | 31.24 |
| Average Volume (20 Days) | 337,209 |
Short Selling Information
The latest short interest is 470,162, so 5.40% of the outstanding shares have been sold short.
| Short Interest | 470,162 |
| Short Previous Month | 472,347 |
| Short % of Shares Out | 5.40% |
| Short % of Float | 5.98% |
| Short Ratio (days to cover) | 2.16 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -32.03M |
| Pretax Income | -30.98M |
| Net Income | -30.68M |
| EBITDA | -31.92M |
| EBIT | -32.03M |
| Earnings Per Share (EPS) | -$9.66 |
Balance Sheet
The company has $22.80 million in cash and n/a in debt, with a net cash position of $22.80 million or $2.62 per share.
| Cash & Cash Equivalents | 22.80M |
| Total Debt | n/a |
| Net Cash | 22.80M |
| Net Cash Per Share | $2.62 |
| Equity (Book Value) | 23.41M |
| Book Value Per Share | 3.32 |
| Working Capital | 21.80M |
Cash Flow
In the last 12 months, operating cash flow was -$30.82 million and capital expenditures -$127,049, giving a free cash flow of -$30.95 million.
| Operating Cash Flow | -30.82M |
| Capital Expenditures | -127,049 |
| Depreciation & Amortization | 112,981 |
| Net Borrowing | n/a |
| Free Cash Flow | -30.95M |
| FCF Per Share | -$3.56 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BCTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1,260.31% |
| Shareholder Yield | -1,260.31% |
| Earnings Yield | -128.26% |
| FCF Yield | -129.41% |
Analyst Forecast
The average price target for BCTX is $150.00, which is 5,315.16% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $150.00 |
| Price Target Difference | 5,315.16% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 25, 2025. It was a reverse split with a ratio of 1:10.
| Last Split Date | Aug 25, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |